Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms
- PMID: 34948375
- PMCID: PMC8703580
- DOI: 10.3390/ijms222413578
Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms
Abstract
Pediatric autoimmune liver disorders include autoimmune hepatitis (AIH), autoimmune sclerosing cholangitis (ASC), and de novo AIH after liver transplantation. AIH is an idiopathic disease characterized by immune-mediated hepatocyte injury associated with the destruction of liver cells, causing inflammation, liver failure, and fibrosis, typically associated with autoantibodies. The etiology of AIH is not entirely unraveled, but evidence supports an intricate interaction among genetic variants, environmental factors, and epigenetic modifications. The pathogenesis of AIH comprises the interaction between specific genetic traits and molecular mimicry for disease development, impaired immunoregulatory mechanisms, including CD4+ T cell population and Treg cells, alongside other contributory roles played by CD8+ cytotoxicity and autoantibody production by B cells. These findings delineate an intricate pathway that includes gene to gene and gene to environment interactions with various drugs, viral infections, and the complex microbiome. Epigenetics emphasizes gene expression through hereditary and reversible modifications of the chromatin architecture without interfering with the DNA sequence. These alterations comprise DNA methylation, histone transformations, and non-coding small (miRNA) and long (lncRNA) RNA transcriptions. The current first-line therapy comprises prednisolone plus azathioprine to induce clinical and biochemical remission. Further understanding of the cellular and molecular mechanisms encountered in AIH may depict their impact on clinical aspects, detect biomarkers, and guide toward novel, effective, and better-targeted therapies with fewer side effects.
Keywords: T cells; autoantibodies; autoimmune hepatitis; autoimmunity; genetic trait; pathogenesis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Mieli-Vergani G., Vergani D., Baumann U., Czubkowski P., Debray D., Dezsofi A., Fischler B., Gupte G., Hierro L., Indolfi G., et al. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. J. Pediatr. Gastroenterol. Nutr. 2018;66:345–360. doi: 10.1097/MPG.0000000000001801. - DOI - PubMed
-
- Waldenstrom J. Leber, Blutproteine und Nahrungseiweiss. Dtsch. Gesellsch. Verd. Stoffw. 1950;15:113–119. - PubMed
-
- Sebode M., Kloppenburg A., Aigner A., Lohse A.W., Schramm C., Linder R. Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: Rising prevalences based on ICD codes, yet deficits in medical treatment. Z. Gastroenterol. 2020;58:431–438. doi: 10.1055/a-1135-9306. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
